DA
ALDX icon

Denali Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Denali Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-47,300
Closed -$155K – 184
2024
Q1 		$155K Buy
+47,300
New +$156K 0.05% 245

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Denali Advisors's ALDX Position: Q2 2024 in Review

Denali Advisors sold out of Aldeyra Therapeutics (ALDX) in Q2 2024, closing a stake of 47,300 shares — an estimated $155K sold.

Denali Advisors first reported a position in ALDX in Q1 2024 and held it in 1 quarter. The position peaked at $155K in Q1 2024. 103 funds tracked by Wall St. Rank hold ALDX as of Q2 2024.

  • Denali Advisors reported no remaining Aldeyra Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Denali Advisors sold 47,300 Aldeyra Therapeutics shares in Q2 2024, an estimated $155K.
  • Denali Advisors first reported a position in Aldeyra Therapeutics in Q1 2024 and held it in 1 quarter.
  • Denali Advisors's Aldeyra Therapeutics position peaked at $155K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2024.

Based on Denali Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.